FDA Early Engagement
A well-executed Pre-Submission meeting is one of the highest-ROI investments in any regulatory program. The right questions, addressed to the right FDA reviewers at the right time, can prevent millions of dollars in avoidable testing, trial design mistakes, and submission failures.
Plan Your Pre-Sub StrategyThe Q-Sub Program
The FDA Pre-Submission (Pre-Sub) program, administered under the Q-Submission (Q-Sub) framework, gives device sponsors a formal mechanism to obtain FDA feedback before filing a marketing submission or beginning a clinical study. It is not a device approval, not a formal regulatory review, and not a binding commitment from FDA. But used correctly, it is one of the most effective risk management tools available in medical device development.
Through a Pre-Sub, sponsors can ask FDA specific, documented questions about: the appropriate regulatory pathway for their device; the adequacy of their proposed testing strategy (nonclinical, bench, animal, clinical); the acceptability of their predicate device selection for a 510(k); the appropriateness of their study design for a PMA clinical trial; the FDA's view on whether clinical data is needed for a specific 510(k); or the special controls framework for a De Novo request. FDA's written responses become part of the administrative record and — while not binding — represent the agency's current position on the questions asked.
Not every situation warrants a Pre-Sub. Filing too early — before sufficient device definition and testing planning exists — results in vague questions and vague answers that don't advance the program. Filing too late — after a testing program is already complete — reduces the value of FDA feedback since the costly decisions have already been made. The optimal window is when you have enough device definition to ask specific questions, but before you've committed to an approach that would be expensive to change.
High-value Pre-Sub situations: novel devices where the regulatory pathway is genuinely unclear; testing strategies for 510(k)s involving complex software, new materials, or new mechanisms of action; clinical study design for PMA pivotal trials (where study design errors are catastrophically expensive to fix post-hoc); IDE applications for first-in-human studies; and De Novo requests where special controls development would benefit from FDA alignment before full submission preparation.
Low-value Pre-Sub situations: well-characterized device types with established regulatory expectations; situations where the applicable guidance documents and recognized standards already answer the question; and situations where the sponsor already has sufficient FDA precedent from recently cleared comparable devices.
The quality of FDA's Pre-Sub response is directly proportional to the quality of the questions asked. FDA reviewers respond to specific, bounded questions — not open-ended requests for general guidance. A question like "Is our testing program adequate?" will get an inadequate answer. A question like "We propose to characterize the device's fatigue performance using [specific test method] with [specific acceptance criteria] based on [specific justification]. Does FDA agree this approach adequately characterizes fatigue for this device type, or are there additional performance tests FDA would expect?" gets a reviewable, actionable answer.
We develop Pre-Sub question packages that are specific, contextualized, and structured to elicit FDA feedback on the exact decision points that matter to your program. We also ensure the background section of the Pre-Sub provides FDA reviewers with the device description, intended use, and relevant regulatory context they need to give an informed response.
Get Started
The companies that reach clearance most efficiently engage FDA early and strategically. We'll tell you whether a Pre-Sub makes sense for your program, what to ask, and when to file it.